EMA accepts pirfenidone MAA

The European Medicines Agency (EMA) accepted for filing an MAA from InterMune Inc. (NASDAQ:ITMN) for Esbriet pirfenidone to treat idiopathic pulmonary fibrosis (IPF). InterMune expects a decision in 1...